Windtree Therapeutics, Inc. · OTC:WINT
Windtree Therapeutics — Investor Presentation (August 2022)
42 slides from Windtree Therapeutics's investor presentation, Aug 11, 2022
Slide 1: Windtree Therapeutics Company Overview
Windtree Therapeutics N Company Overview August 11, 2022 Sse we WINDTREE (NASDAQ: WINT)
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27Aof the Securities Actof 1933, as amended, and Section 21E ofthe Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company's
Slide 3: Windtree Therapeutics and Istaroxime Highlights
Windtree Therapeutics and Istaroxime Highlights v v Biopharmaceutical company with advanced clinical focused on significant acute CV markets with high unmet needs and with supportive regulatory paths and designations (NASDAQ: WINT) Through three Phase 2 global studies, lead asset istaroxime has cons
Slide 4: Pipeline
Pipeline Lead Products _ Indication Phase Istaroxime Acute Heart Failure Phase 2b Istaroxime Early Cardiogenic Shock Phase 2 Oral SERCA2a Rakai Chronic HF; potentaly HFpEF ——_—Prectnical KL4Surfactant— COviO 19Pilot, Possible invasive pace > COVID19 ‘Tx for RDS in neonates ‘AEROSURF We sufeclant Dru
Slide 5: Strategy for Value Creation
Strategy for Value Creation 2022 2023 2024 Q2 Q3 Q4 Qi Q2 Q3 Q4 Qi Q2 Q3 Istaroxime Cardiogenic Shock FDAEOP2 Phase 2 ' par (SEISMIC) ~| Early Cardiogenic Shock Positive | Registration Study* 4 Results ees sits Istaroxime Heart Failure Acute Heart Failure Study ~18 month o execute; Ph, potenti! (tra
Slide 6: Istaroxime: Early Cardiogenic Shock
Istaroxime Early Cardiogenic Shock Additional potential indication in active clinical development
Slide 7: Cardiogenic Shock
Cardiogenic Shock Asevere presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high filling pressures of the heart and decreased urine output. Itisa treatment emergency » Caused by severe impairment of cardiac function that results in diminished car
Slide 8: Early Cardiogenic Shock Treatment: Market Research
jarket Research’ Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity to Address Significant Unmet Need ~ No satisfactory pharmacological intervention to reverse the conditions Available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, renal
Slide 9: Istaroxime: Novel First-in-Class Therapy
Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart Dual Mechanism of Action ‘Stimulation of SERCA2a activity Inhibition of the sodium- ® enhances calcium reuptake potassium pump and effects on i tho sodumca
Slide 10: Rationale for Istaroxime in Cardiogenic Shock Came from AHF Phase 2 Trials
Rationale for Istaroxime in Cardiogenic Shock Came from AHF Phase 2 Trials E/e’ (cardiacfilling pressure) Systolic Blood Pressure (SBP) Istaroxime 1.0 yg/kg/min vs. placebo Istaroxime 1.0 yg/kgimin vs. placebo 7 * I 1 et + paue= 0011 ‘ i. * pales <0. 006 Improved : cardiac function ; — | si, and SBP
Slide 11: Early Cardiogenic Shock Treatment: Accelerated Pathway
Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Pathway Potential for a relatively fast and less expensive developmental and regulatory pathway Sponsors are potentially not required to show benefit other than an FDA Regulatory increase in blood pressure to support
Slide 12: SEISMiC Early Cardiogenic Shock Study
SEISMiC Early Cardiogenic Shock Study Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure ] p 60 patients in early cardiogenic shock (SBP 75-90mmHg) with AHF Study drug was infused for 24 hours in a 1:1 randomization to placebo or istaroxime.
Slide 13: Difference in SBP Profile
020 Difference in SBP Profile Systolic Blood Pressure AUC through 6 Hours - mITT Population Bi staroxime Placebo mmHg) SBP ( in Change from Baseline i o os 1 iS 2s 3 SaaS SSS 8g Hours from Infusion Inititation _ WINDTREE fa)
Slide 14: Secondary Results
\ Secondary Results _ Systolic BP Improvements Persisted over 24 Hours Systolic Blood Pressure mITT Population 20 46 —*Istaroxime 3 © Placebo z E & re 3 £ 6 { p=0.025 for AUC Atal ° 0 12 24 Hours from Infusion initiation a6 WINDTREE “
Slide 15: Cardiac Function Improvement
Cardiac Function Improvement Echocardiography demonstrated improvements in key systolic and diastolic cardiac function measures including: * Cardiac index significantly increased » Stroke volume index substantially increased (4 mL/m?) approaching statistical significance * Other echocardiographic me
Slide 16: Treatment was Associated with a Favorable Renal Profile
Treatment was Associated with a Favorable Renal Profile Renal function was not decreased in istaroxime treated patients ,—_________ Estimated Glomerular Filtration Rate mITT Population {GER (riini3.73m%) Fr a Z Boa 3 E coils é = © Placebo 7 a a a on ore oe i 2 Pa % @ Pa 2 ee ra ours trom nuston inio
Slide 17: Comparison of Doses
b Comparison of Doses 1.0 pg/kg/min Produced a Favorable Effect on SBP 4.0 ugikgimin dosing was associated with: ~ Early, rapid SBP increase and improvement in more echocardiographic assessments of cardiac function + More favorable adverse event, serious adverse event and clinical event profile 21.0
Slide 18: SEISMIC Results Summary
SEISMIC Results Summary SEISMIC was a positive study in early cardiogenic shock patients v Systolic blood pressure significantly increased within the first 6 hours of initiating the infusion (p=0.017) and the increase was maintained throughout the 24-hour infusion (p=0.025) » SBP increases were rapi
Slide 19: Relevance to the Acute Heart Failure (AHF) Program
Na Relevance to the Acute Heart Failure (AHF) Program » The early cardiogenic shock trial results are consistent with Windtree’s Phase 2 AHF studies and complementary to further advancement in AHF. » While SEISMIC was an early cardiogenic shock study, the patients studied had very severe AHF providi
Slide 20: Cardiogenic Shock Development Strategy
Cardiogenic Shock Development Strategy SEISMIC Extension Study = Extended and titrated dosing for optimization SE ic ‘= Additional characterization Phase 3* ISMi Of SERCAZA effect = Execute EOP2 meeting Study with these 3 studies augmented by AHF Proof of Concept ey safety data base, etc. SCAI Stage
Slide 21: Plan for Dose Optimization: Extension Study
Plan for Dose Optimization — Extension Study Following the positive results in the early cardiogenic shock study, an extension study is planned to support ongoing development in early cardiogenic shock and acute heart failure Study objectives: v Advance the characterization of the physiology associa
Slide 22: Istaroxime: Acute Heart Failure
Istaroxime Dual Mechanism SERCA2a Activator Acute Heart Failure
Slide 23: Heart Failure: Large, Growing Market But Underserved
Heart Failure - Large, Growing Market But Underserved The prevalence and mortality of heart failure is high and increasing #1 cause of U.S. Annual Admissions Patients hospitalization ~1.3M us 7Mus . wi in patients ~1.5M ev. 25M * wortawiae > 65 years old ES ~7T% (oy >$18B co 0 In-patient mortality a
Slide 24: Acute Heart Failure: Significant Unmet Clinical Need
Acute Heart Failure — Significant Unmet Clinical Need tient Management Goals urrent Treatment Options * Clinical objectives for AHF » Current approaches to acutely improve cardiac patient management include: function are associated with unwanted effects: Relieve pulmonary congestion Heart rhythm dis
Slide 25: Istaroxime AHF Phase 2a & 2b Studies
Istaroxime AHF Phase 2a & 2b Studies * Primary: PCWP significantly improved Phase * Stroke Vol & SBP ~ significantincrease 2a n=120 Dosing= 6 hour + Heart Rate (HR) - lowered ADHF Patients 0.5, 1, 1.5 ygkgimin Infusion Phase n=120 Dosing= 24 hour 2b ADHF Patients 0.5, 1.0 voksimin Infusion (aysenea
Slide 26: Primary Endpoint Achieved
Primary Endpoint Achieved Significant Changes in E/e' Ratio’ and Stroke Volume WINDTREE Istaroxime 0.5 ug/kg/min vs. placebo + Placebo -Cohor infusion period * pwvalue = 0.029 —eisrcrine 15 voto Infusion period Ele’ |), Et echocarsograpicassessmentotPCWP; Note Oatashown.as means andstandard ears Ist
Slide 27: Systolic Blood Pressure Increased and Renal Function Tended to Improve
Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve Istaroxime 0.5 ug/kgimin vs. placebo Istaroxime 1.0 ug/kgimin vs. placebo Le Systolic 3° + paar oon Hi Blood = * rad ag? Pressure 5 ° H (SBP) Zo i: Bs a é é E © Pete Cont? elaine 109K » 6 eo ; is] GFR i Lal (Rena
Slide 28: Heart Rate Decreased and No Increases in Cardiac Troponins
Heart Rate Decreased and No Increases in Cardiac Troponins Istaroxime 0.5 yg/kgimin vs. placebo Istaroxime 1.0 ug/kgimin vs. placebo i, Heart re Rate ts a *pralue= 0.014 a *pvalue=0.011, 2 eel at place Os a Pasts-Cinatt metroid iainn Sree hante-tomn? gtavexnet sean eTnT-0t0 24 hours 7 eTnT=24to 72 h
Slide 29: Favorable Profile Observed with 24-hour Holter Monitoring
Favorable Profile Observed with 24-hour Holter Monitoring Clinically Significant Arrhythmias 1208 250% 708% 10am 108% aca. sao | 220% 200% 200% Eom: 288 ee, 100% 100% 40% om 24% 24% 24% 00% oo L — a Baseline ay 1 (rtsen) ay 2 Bassiee ay (sor) a2 sPacebo-Cahot + alascrime 05 vakgimn Placebo - Conon 2
Slide 30: Istaroxime: Acute Heart Failure Phase 2c
2c Istaroxime — Acute Heart Failure Objective: Optimize therapy and employ study enrichment strategies to create strong Phase 3 and partnership position Execute an additional study designed to complete Phase 2 and inform Phase 3 - 300 patients, 60 centers globally Enrich therapeutic impact by levera
Slide 31: Next Generation, Oral SERCA2a Activators Platform
Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCA2a Dual Mechanism, (SERCA2a & Na+/K+) Activators Compounds + Oral & i.v. therapies for chronic “Next generation istaroxime” as
Slide 32: Summary
Summary rg Istaroxime has produced positive, differentiating data in three Phase 2 studies for two separate and complementary indications. These markets have significant unmet needs, and no known other late-stage programs in development to address the acute decompensated patient ~ The data is consis
Slide 33: Financial Summary & Capitalization
Financial Summary & Capitalization Cash & Equivalents of ~$11.4 million as of June 30, 2022 Common Equivalents Securities as of August 11, 2022 Common Stock 30,627,878 Options (WAEP $7.84) 4,046,604 Restricted Stock Units 560,900 Warrants (WAEP $6.64) 16,546,336 Fully Diluted Equivalents. 51,781,718
Slide 34: Strategy for Value Generation
Strategy for Value Generation Communicate Our Milestones Transactions WA Optimization ie Secure focused BD Bring in new, well- transactions fordeal revenue Suited development and non-dilutive financial supportof clinical opportunities and development transactions Progress heart failure platformto an
Slide 35: Slide 35
Slide 36: Appendix
Appendix se ce WINDTREE
Slide 37: Istaroxime Unique Opportunity With Attractive Risk / Return Profile
Istaroxime Unique Opportunity With Attractive Risk / Return Profile @ Hichy consistent results across 3 @© Attractive profile as the only acute heart failure or shock drug that has controlled Phase 2 studies (and been shown to significantly improve cardiac function of a failing heart, 300 patients d
Slide 38: Istaroxime AHF Phase 2b Adverse Events
Istaroxime AHF Phase 2b Adverse Events Pooled placebo _—Istaroxime 0.6 mg/Kgimin _Istaroxime 1.0 mg/Kgimin (n=39) (n=41) (n=40) All adverse events 23 (59.0%) 31 (75.6%) 33 (625%) ‘Adverse events leading to discontinuation 1 (26%) : 4(100%) Serious adverse events 206.1%) 2(49%) 6(150%) Cardiac death
Slide 39: SEISMIC: Serious Adverse Events and Adverse Drug Reactions
SEISMIC: Serious Adverse Events and Adverse Drug Reactions Istaroxime Placebo (N=29) (N=31) All adverseevents 27 (93%) 25 (81%) Seriousadverse events 6 (19%) Cardiac arrest ° Cardiac failure 2 (6%) Cardiac failure acute 1 (3%) ventric i 1(3%) Cardiac artery 1(3%) Ventricular fibrillation Ventricular
Slide 40: SEISMiC: Safety and Efficacy More Favorable with 1.0 vs 1.5 ug/kg/min
SEISMiC: Safety and Efficacy Appeared More Favorable with the 1.0 vs 1.5 pg/kg/min and Placebo 1.0 ug/kg/min dosing was associated with: Istaroxime Istaroxime Placeb clinical Events by Dose Statistic Nest), Sroka rt cao [SBP AUC 0-24hrs LS-Means(SE)* 209.9(27.38) 282.7 (35.79) 304.1 (44.11) ‘Worseni
Slide 41: Acute Heart Failure: Significant Unmet Clinical Need
Acute Heart Failure Significant Healthcare Issue with Significant Unmet Clinical Need * Patients with low blood pressure (SBP) and peripheral hypoperfusion are high risk, challenging patients. These patients are also generally resistant to diuretic therapy and often discharged in a sub-optimal state
Slide 42: Istaroxime Phase 2a (HORIZON-HF) Study
Istaroxime Phase 2a (HORIZON-HF) Study + Multicenter, double blind, placebo-controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU ~ Hospitalized with AHF, with criteria including: LVEF s 35% ‘SBP 90-150 mmHg + N=120 (30/group) * Significant improvement in PCWP,
Windtree Therapeutics — Investor Presentation (August 2022) on 6ix